Avita Medical
RCEL
69 hedge funds and large institutions have $58.3M invested in Avita Medical in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 15 increasing their positions, 21 reducing their positions, and 15 closing their positions.
1,241% more call options, than puts
Call options by funds: $5.97M | Put options by funds: $445K
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
11% more funds holding
Funds holding: 62 → 69 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.34% less ownership
Funds ownership: 29.95% → 27.61% (-2.3%)
29% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 21
35% less capital invested
Capital invested by funds: $89.4M → $58.3M (-$31.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$6.21M |
| 2 |
Renaissance Technologies
New York
|
+$1.98M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.03M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$583K |
| 5 |
MA
MCF Advisors
Covington,
Kentucky
|
+$339K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$8.05M |
| 2 |
BC
Blackcrane Capital
Bellevue,
Washington
|
-$3.79M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.35M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$684K |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$595K |
RCEL Hedge Fund Activity: Q1 2022 in Review
69 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Avita Medical (RCEL) for Q1 2022, worth a combined $58.3M — down 35% from $89.4M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RCEL positions and 15 closed out — a net gain of 7 holders — while 15 added to existing stakes and 21 trimmed.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $6.21M. The largest seller was Redmile Group, exiting entirely with an estimated $8.05M sold.
- 69 institutional investors held Avita Medical (RCEL) as of Q1 2022, up from 62 in Q4 2021.
- Funds reported $58.3M of Avita Medical stock for Q1 2022, down 35% quarter-over-quarter.
- 22 funds opened new Avita Medical positions in Q1 2022 and 15 closed out, a net change of +7 holders.
- The largest Avita Medical buyer in Q1 2022 was Pura Vida Investments, an estimated $6.21M added.
- The largest Avita Medical seller in Q1 2022 was Redmile Group, an estimated $8.05M sold.
Based on aggregated 13F filings for Q1 2022.